AIDSWEEKLY Plus; Monday, December 18, 2000
Prepared by AIDS Weekly editors from staff and other reports

This organ, called the thymus, is especially important early in life when the human immune system is developing. Infants who contract the virus from their mothers are particularly prone to developing immune system problems because of the damage HIV ultimately causes to the thymus.

Pregnant mothers who are HIV positive are often given AZT, a drug that helps prevent the fetus from contracting the virus. In children and adults with HIV, AZT helps control and even reduces the proliferation of the virus in the blood.

Researchers at Ohio State University tested the effect of the drug AZT on the thymuses of young cats infected with FIV, a virus which behaves similar to HIV and one that causes an AIDS-like disease in cats.

They found that although AZT helped control and even reduce the amount of FIV in the blood and in the thymus, the virus still was able to cause significant physical damage to the thymus.

"This lack of protection surprised us," said Larry Mathes, a study co-author and a professor of veterinary biosciences at Ohio State. "It suggests that antiviral therapy in infants may need to be combined with other treatments - such as other drugs - in order to restore thymic function."

The study was published in the journal Antimicrobial Agents and Chemotherapy.

The researchers already knew that AZT reduces the levels of FIV and HIV in blood outside of the thymus. Cats were placed into one of four groups. In the first, cats were infected with FIV and treated with AZT. In a second, the animals were infected with FIV and treated with placebo. The third contained uninfected, AZT-treated cats, and in the fourth, the cats remained uninfected and received only a placebo instead of AZT.

The cats received daily doses of AZT for 12 weeks. Treatment began two days before the cats were infected with the virus, so researchers could compare the levels of certain immune system cells - T cells - in the infected and uninfected groups. The virus attacks and kills T cells, which mature in the thymus.

Levels of virus present in the blood samples were determined at four, eight, and 12 weeks after the initial infection. The experiments ended after 12 weeks and the researchers examined the animal's thymus glands for signs of infection.

Animals receiving the AZT treatment showed significantly reduced (by 75% to 85%) levels of virus in the blood and also in the thymus (by about 74%) when compared to animals which were infected but not treated. Yet the FIV had ultimately caused similar physical damage and inflammation to the thymuses of the cats in both of the infected groups.

Inflammation is a typical immune response to a virus or an injury; it's part of the healing process. The immune system tried to get rid of the virus in the thymus, so it launched an attack, which caused the inflammation. But reducing the virus level didn't cause the inflammation to subside.

"We're not sure why it didn't," Mathes said. "It would make sense that a decrease in virus levels would mean that the inflammation would subside and that the thymus would improve. Since that didn't happen, we assumed that it was the immune response that ended up damaging the thymus.

"Our long-term goal is to develop a therapeutic strategy to protect the thymus," Mathes continued. "We want to find how we can protect it."

The research was supported by grants from the U.S. National Institutes of Health and the U.S. National Institute of Allergy and Infectious Diseases.

This article was prepared by AIDS Weekly editors from staff and other reports.

001218
AW001202

Copyright © 2000 - Charles Henderson, Publisher. All rights Reserved. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633-4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX: (205) 995-1588 http://www.newsrx.net

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, iMetrikus, Inc., John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1990, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.